Taken together, these data indicate that simultaneous blockade of IGF-IR and EGFR/Her-2 using NVP-AEW541 and lapatinib may overcome resistance in pancreatic cancer. This evidence concerns the gene ERBB2 and familial pancreatic carcinoma.